Hints and tips:
Related Special Reports
Related Topics
...In October 2019, Merck also completed a €5.8bn acquisition of US-based Versum Materials, which makes critical components used in semiconductors. Merck declined to comment....
...In October 2023 Merck’s research chief called on the government to make Britain more welcoming to pharma companies, even as the US-based drugmaker prepared to break ground on a £1bn research centre in London...
...The news mark another disappointment for Merck, which two years ago halted work on a cancer drug that had also been hailed as a potential blockbuster....
...Merck estimates that 2.8mn people have MS, a neurological condition with symptoms including balance and movement problems, pain and tiredness....
...Merck KGaA chief Belén Garijo will be all too aware of the highs and sudden crushing lows of drug trials....
...Merck cut its full year earnings outlook because of a charge related to its $22bn partnership deal with Japanese group Daiichi Sankyo, as the US pharma group invests in cancer drugs....
...Merck Mercuriadis, adviser to Hipgnosis Songs Fund, has offered to drop a controversial clause giving him the right to buy the group’s music portfolio as he battles to stay on at the investment trust he...
...Merck said it will record a pretax charge of $5.5bn as a result of the deal....
...Dean Li, president of Merck’s research laboratories, praised the UK’s scientific talent and expertise, hoping that the investment in King’s Cross will help researchers at MSD, known as Merck in the US, work...
...Merck knows how that feels. Its shares slumped 12 per cent on Wednesday after a multiple sclerosis medicine flopped in late-stage trials....
...Merck raised its full year revenue forecasts to between $58.6bn and $59.6bn, up from an earlier forecast of $57.7bn and $58.9bn....
...Opdivo actually outperformed Keytruda in product sales from 2014 to 2017, at which point Merck’s lifecycle efforts paid off, and it has since been far more successful....
...Big share price moves in Europe on Wednesday include German tour operator Tui, German pharmaceutical company Merck, and London-listed British American Tobacco: Tui: Shares in the tour operator surged 6.3...
...Investment adviser and music mogul Merck Mercuriadis was a frontman as crowd-pleasing as any stadium rocker The net asset value rose from a few hundred million dollars to $2.2bn at the end of last year....
...New data from Moderna and Merck this week offered a promising update on this front....
...And it violates the constitution in at least two obvious respects,” said Merck in a court filing....
...Merck will pay the Chinese company €160mn upfront as part of the deal. Broker Jeffries cut its target price for Merck to €173 from €201....
...And what are the incentives of Merck Mercuriadis after the transaction?...
...By October, JSR’s board had considered and rejected Merck’s proposal, arguing that there was insufficient synergy....
...The deal comes as pharmaceutical companies gather in San Francisco for an annual industry conference, with GSK rivals Johnson & Johnson, Novartis and Merck announcing acquisitions on Monday....
...Merck Mercuriadis, who established Hipgnosis in 2018 and is now chief executive of the fund’s investment adviser — Hipgnosis Song Management — said the AGM “marks an opportunity to reset and focus on the...
...He said Merck’s claim that the reforms were an “extortion” was accurate....
...A person familiar with the process said Merck “understood there was no hope . . . [Lagevrio] is a bit burnt”....
...Merck Mercuriadis, a former manager of stars including Beyoncé and Elton John, established Hipgnosis in 2018 and listed it in London as an investment trust....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
International Edition